Compare Fidelity National Information Servcs Inc (FIS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Recursion Pharmaceuticals Inc — how do they compare? Fidelity National Information Servcs Inc trades at $34.49 (market cap $17.71B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Fidelity National Information Servcs Inc is far larger — about 8.3× Recursion Pharmaceuticals Inc's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FIS | RXRX | |
|---|---|---|
Market Cap | $17.71B | $2.14B |
Volume | 9,047,825 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $68.57 | $6.79 |
52-Week Low | $32.44 | $2.84 |
Typical Hold Time | 88 Days | 22 Days |
Enterprise Value | $38.22B | $1.66B |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $33.82, up 1.2% today, with a bearish technical signal and neutral oscillators. The stock shows attractive valuation with a P/E of 5.2 and P/S of 1.44, supported by a 27.65% net income margin and 22.33% ROE. Recent earnings beat expectations in Q1 and Q2 2026, and the company secured multiple core banking client wins, enhancing growth prospects.
Outlook is positive given low valuations and earnings momentum, but risks include high debt levels and inconsistent cash flow. Analyst consensus is bullish with a $47.54 price target, implying significant upside. Investors should monitor execution on revenue growth and debt management.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
